Expert Interview
Discussing the potential of Zilebesiran, an inhibitor of hepatic angiotensinogen synthesis, in development by Alnylam Pharmaceuticals as an injection for patients with hypertension.
Ticker(s): ALNYInstitution:
- Director of Echocardiography Lab and Staff Cardiologist at Overlake Medical Center & Clinics
- treats 800 patients with hypertension
- Clinical and Research interest advance cardiovascular imaging, echocariography, valvular heart disease, and heart failure.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
